Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
neurodegeneration
Biotech
Lilly pays QurAlis $45M for preclinical ALS, dementia prospect
The deal gives Lilly global rights to QRL-204, a splice-switching antisense oligonucleotide designed to restore UNC13A function.
Nick Paul Taylor
Jun 3, 2024 5:00am
AbbVie continues Parkinson's pursuit with $110M Mitokinin buy
Oct 5, 2023 10:30am
BMS pays $95M to exercise Evotec, Prothena neuroscience options
Jul 11, 2023 5:30am
Biogen trims Denali-partnered Parkinson's program in half
Jun 5, 2023 10:50am
Mount Sinai unveils 3-branch regenerative medicine institute
Apr 24, 2023 3:25pm
EQT Life Sciences closes €260M dementia fund
Mar 29, 2023 5:32am
